Effets de la Thérapie d'Un An Par Tofacitinib Sur le Métabolisme Osseux Dans la Polyarthrite Rhumatoïde
Osteoporos Int 2021 Feb 9 DOI 10.1007/s00198-021-05871-0
Thought to be the first study of its kind, Hamar, et al. have demonstrated the effect of one-year tofacitinib treatment on bone mineral density (BMD) in RA patients. While the association between RA and osteoporosis is well known, and evidence indicates that up to 70% of these patients have reduced BMD, little information is available on how the JAK inhibitor tofacitinib affects bone status, areal and volumetric BMD, and bone turnover markers. In this prospective study, 30 patients were assessed...